TP53 and neoplasm: While the research did not demonstrate the effectiveness of TILs or TCR-engineered T cells in reducing tumor size, it did provide strong proof that endogenous p53 mutants in human tumor cells are immunogenic, which opens doors for using mutant p53-based ACT therapies.